Myrexis Initiates Comparative-Arm Phase 2 Study of Azixa(TM) for the Front-Line Treatment of Glioblastoma Multiforme
22 déc. 2010 16h19 HE
|
Myrexis, Inc.
SALT LAKE CITY, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Reports Anti-Tumor Activity in a Subset of Patients From Ongoing Phase 2 Azixa(TM) Study in Recurrent Glioblastoma Multiforme at Society for Neuro-Oncology
19 nov. 2010 09h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 19, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Present at Piper Jaffray Health Care Conference
18 nov. 2010 09h20 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 18, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Presents Data on Cancer Metabolism Inhibitor at 22nd EORTC/NCI/AACR Symposium
17 nov. 2010 08h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 17, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Reports First Quarter Fiscal 2011 Financial Results
09 nov. 2010 16h21 HE
|
Myrexis, Inc.
AzixaTM Two-Arm Phase 2b Study in Glioblastoma to Begin by Calendar Year-End
Received ~$1.2M Section 48D Tax Grant
Conference Call Today at 4:30pm EST
Upcoming Events
Initiate two-arm...
Myrexis Presents Oral Anti-Interferon Data at American College of Rheumatology/Association of Rheumatology Health Professionals
08 nov. 2010 07h55 HE
|
Myrexis, Inc.
SALT LAKE CITY, Nov. 8, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Hold Conference Call to Discuss Fiscal First Quarter 2011 Financial Results and Azixa(TM) Phase 2b Study Plans
28 oct. 2010 09h15 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 28, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Present Updated Results From Ongoing Phase 2 Azixa(TM) Study in Glioblastoma Multiforme at Society for Neuro-Oncology
21 oct. 2010 14h38 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 21, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis to Present Oral Anti-Interferon Program at American College of Rheumatology/Association of Rheumatology Health Professionals
06 oct. 2010 14h54 HE
|
Myrexis, Inc.
SALT LAKE CITY, Oct. 6, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...
Myrexis Presents Key Findings From Its Cancer Metabolism Inhibitor, MPC-9528
20 sept. 2010 07h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 20, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today...